18:12 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Ascentage reports Phase I safety data for IAP inhibitor in solid tumors

Ascentage Pharma Group Corp. Ltd. (Hong Kong, China) said IV APG-1387 once every week for three out of four weeks in each 28-day cycle was well tolerated with manageable adverse events in 28 evaluable patients...
22:20 , Jan 13, 2017 |  BioCentury  |  Finance

Advancing apoptosis

A RMB500 million ($72 million) series B round will enable Ascentage Pharma Group Corp. Ltd. to generate clinical proof-of-concept data for two to three cancer candidates in three years. Future Industry Investment Fund led the...
02:08 , Aug 14, 2015 |  BC Extra  |  Financial News

Ascentage Pharma raises $15.5M in series A

Ascentage Pharma Group Corp. Ltd. (Hong Kong, China) raised $15.5 million in a series A round led by Oriza Seed Capital and YuanMing Capital. EFung Capital; BioVenture Capital; Grains Valley Venture Capital; and undisclosed investors...